Replimune to Present at Two Upcoming Investor Conferences
August 01 2023 - 8:00AM
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage
biotechnology company pioneering the development of a novel
portfolio of tumor-directed oncolytic immunotherapies, today
announced that members from the Replimune management team will
present and host investor meetings at the following two
conferences:
BTIG Virtual Biotechnology Conference 2023Date: Tuesday, August
8, 2023Fireside Chat Time: 1:30 pm EDT
2023 Wedbush PacGrow Healthcare Conference Date: Wednesday,
August 9, 2023Location: Lotte Palace Hotel, New York, NYIn-person
1x1 investor meetings only
About Replimune Replimune Group, Inc.,
headquartered in Woburn, MA, was founded in 2015 with the mission
to transform cancer treatment by pioneering the development of
novel tumor-directed oncolytic immunotherapies. Replimune’s
proprietary RPx platform is based on a potent HSV-1 backbone with
payloads added to maximize immunogenic cell death and the induction
of a systemic anti-tumor immune response. The RPx platform has a
unique dual local and systemic mechanism of action consisting of
direct selective virus-mediated killing of the tumor resulting in
the release of tumor derived antigens and altering of the tumor
microenvironment to ignite a strong and durable systemic response.
This MOA is expected to be synergistic with most established and
experimental cancer treatment modalities, and, with an attractive
safety profile the RPx platform has the versatility to be developed
alone or combined with a variety of other treatment options. For
more information, please visit www.replimune.com.
Investor Inquiries Chris BrinzeyICR
Westwicke339.970.2843chris.brinzey@westwicke.com
Media InquiriesArleen
GoldenbergReplimune917.548.1582media@replimune.com
Replimune (NASDAQ:REPL)
Historical Stock Chart
From Apr 2024 to May 2024
Replimune (NASDAQ:REPL)
Historical Stock Chart
From May 2023 to May 2024